KalVista Pharmaceuticals (KALV) Net Cash Flow (QoQ) (2014 - 2025)
KalVista Pharmaceuticals (KALV) Net Cash Flow (QoQ) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 74.30% |
| Oct 31, 2024 | 16,179.31% |
| Jul 31, 2024 | -100.66% |
| Apr 30, 2024 | 125.91% |
| Jan 31, 2024 | -483.67% |
| Oct 31, 2023 | 228.15% |
| Jul 31, 2023 | 76.06% |
| Apr 30, 2023 | -162.77% |
| Jan 31, 2023 | 14,126.52% |
| Oct 31, 2022 | -104.39% |
| Jul 31, 2022 | 152.54% |
| Apr 30, 2022 | -3,536.06% |
| Jan 31, 2022 | 78.74% |
| Oct 31, 2021 | 18.12% |
| Jul 31, 2021 | -106.85% |
| Apr 30, 2021 | 2,986.63% |
| Jan 31, 2021 | 169.82% |
| Oct 31, 2020 | -177.17% |
| Jul 31, 2020 | 176.10% |
| Apr 30, 2020 | 21.37% |